The stem cell market size was USD 14.7 billion in 2020 and is estimated to register a substantial CAGR of over 8.8% during the forecast period, 2021–2028. The growth of the market is attributed to increasing number of clinical trials and the growing adoption of stem cell therapies globally.
Stem cell refers to biological cells that can differentiate into other types of cells. Furthermore, several types of stem cells are used for therapeutic purposes. With numerous applications at the clinical stage for various diseases, these are being explored extensively by a large number of biopharmaceutical companies in recent times.
The Covid-19 pandemic had a positive impact on the stem cell market. Ggovernment organizations in several research institutes, countries, and many biotech and pharmaceutical firms are aiming for rapid and effective technologies for the fast diagnosis of COVID-19. According to a research article published in the scientific journal Aging and Disease (2020), mesenchymal stem cells are a safe and effective approach to the treatment of COVID-19; therefore, least 10 projects have been registered in the official international registry for clinical trials, implicating the use of mesenchymal stem cells to patients with corona virus pneumonia.
Market Trends, Drivers, Restraints, and Opportunities
- Growing demand for biologics, technological advancement in stem cell therapeutics, and a growing focus on the development of personalized medication are expected to drive the market during the forecast period.
- Increasing focus on the treatment of neurological disorders is likely to boost the stem cell market.
- Growing popularity of personalized medicines is estimated to propel the market. Researchers are discovering new procurement methods that can be further applied for developing personalized medicines.
- R&D investment and technological advancement in stem cell market are expected to offer lucrative opportunities for the market players.
Scope of the Report
The report on stem cell market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes
|
Details
|
|
Report Title
|
Stem Cell Market –Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
|
|
Base Year
|
2020
|
|
Historic Data
|
2018–2019
|
|
Forecast Period
|
2021–2028
|
|
Segmentation
|
Product Type (Adult Stem Cell, Human Embryonic Cell, Pluripotent Stem Cell, and Other Product Types), Application (Neurological Disorders, Orthopedic Treatments, Oncology Disorders, Injuries and Wounds, Cardiovascular Disorders, and Other Applications), Treatment Type (Allogeneic Stem Cell Therapy, Auto logic Stem Cell Therapy, and Syngeneic Stem Cell Therapy)
|
|
Geography
|
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
|
|
Report Coverage
|
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
|
|
Key Players Covered in the Report
|
Thermo Fisher Scientific, Becton, Dickinson and Company, Stemcell Technologies Inc., Merck KGaA(Sigma Aldrich), and PLURISTEM THERAPEUTICS INC.
|
Market Segment insights
The adult stem cell segment is projected to constitute a large market share
Based on product type, the stem cell market is segregated into adult stem cell, human embryonic cell, pluripotent stem cell, and other product types. The adult stem cell segment is expected to account for a key share of the market during the forecast period owing to the presence of minimal controversial issues concerning immune-rejection, ethics, and tumorigenesis. Furthermore, the application of ASCs in regenerative medicines is likely to boost the market; however, pluripotent stem cell segment is anticipated to expand at a rapid pace during the forecast period owing to increasing investment for developing regenerative medicines using iPSC, ensured reproducibility and maintenance which is capable of differentiation into all the cell types and high proliferative ability.
The oncology disorders segment is expected to register a substantial CAGR
Based on applications, the stem cell market is divided into neurological disorders, orthopedic treatments, oncology disorders, injuries and wounds, cardiovascular disorders, and other applications. The oncology disorders segment accounts for a key share of the market and is estimated to propel even further over the forecast period owing to increasing burden of cancer. According to the World Cancer Research Fund, in 2018, there were an estimated 18 million cancer cases around the globe which is anticipated to boost the segment growth.
The allogeneic stem cell therapy segment is anticipated to dominate the market
Based on treatment type, the stem cell market is divided into allogeneic stem cell therapy, auto logic stem cell therapy, and syngeneic stem cell therapy. The allogeneic stem cell therapy segment accounts for a key share of the market and is anticipated to grow at a rapid pace over the forecast period owing to their graft vs-cancer effect for the treatment of cancer, it helps stem cells from the donor which can use their immune system cell for killing cancer cells. Moreover, these are commonly used for treating different types of cancers such as lymphomas, leukemias, and myelomas.
North America is expected to dominate the market
In terms of geography, the market is broadly classified into Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market in North America is anticipated to expand at a robust CAGR during the forecast period. Several factors such as advanced healthcare infrastructure, the presence of key players engaged in developing stem cell therapies, supportive reforms from healthcare organizations, extensive R&D, and strong reimbursement policies in this region is expected to drive the market growth in near future.
Segments
The stem cell market has been segmented on the basis of
Product Type
- Adult Stem Cell
- Human Embryonic Cell
- Pluripotent Stem Cell
- Other Product Types
Application
- Neurological Disorders
- Orthopedic Treatments
- Oncology Disorders
- Injuries and Wounds
- Cardiovascular Disorders
- Other Applications
Treatment Type
- Allogeneic Stem Cell Therapy
- Auto logic Stem Cell Therapy
- Syngeneic Stem Cell Therapy
Regions
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Companies
- Thermo Fisher Scientific
- Becton, Dickinson and Company
- Stemcell Technologies Inc.
- Merck KGaA(Sigma Aldrich)
- PLURISTEM THERAPEUTICS INC.
Competitive Landscape
Key players competing in the stem cell market include Thermo Fisher Scientific, Becton, Dickinson and Company, Stemcell Technologies Inc., Merck KGaA(Sigma Aldrich), and PLURISTEM THERAPEUTICS INC.
Some of these players are using several market strategies such as mergers, acquisitions, partnerships, collaborations, capacity expansion, and product launches to enhance their market shares. For instance,
- In August 2020, Cipla and Stempeutics joined forces to launch Stempucel cell therapy to treat critical limb ischemia.
- In March 2021, OrganaBio started HematoPAC HSC-CB CD34 hematopoietic stem cell (HSC) product, which aids in supporting HSC-based allogeneic cell therapies.
Request For Customization
Enquiry Before Buying
Speak With Analyst
